Completed PHASE1 INTERVENTIONAL 7-arm NCT03762031

A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

Sponsor: Galera Therapeutics, Inc.

Conditions Healthy

Interventions GC4711 105mg GC4711 120mg GC4711 30mg GC4711 60mg GC4711 75mg GC4711 90mg Placebo

Updated 7 times since 2019 Last updated: Aug 12, 2020 Started: Mar 19, 2019 Primary completion: Mar 4, 2020 Completion: Mar 4, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Galera Therapeutics, Inc. and has accumulated 7 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Oct 2019 — Sep 2020 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Sep 2019 — Oct 2019 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jan 2019 — Sep 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Galera Therapeutics, Inc.

Data source: Galera Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia